EUVIMEDEUVIMED entdecken
Crossref

Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan

Satoshi Kamio iD, Koichi Ogura iD, Yoshiyuki Suehara, Rina Kitada, Masachika Ikegami, Kuniko Sunami, Takafumi Koyama iD, Noboru Yamamoto iD, Seiji Shimomura, Hiroya Kondo iD, Toshiyuki Takemori iD, Shuhei Osaki und 4 weitere

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyaf174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Satoshi Kamio und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ewing sarcoma (ES) is a malignant type of bone and soft tissue tumor with EWSR1–ETS gene fusions as the primary driver alteration. Incidence is higher in White populations compared to Black and Asian populations. Researchers use next-generation sequencing to identify alterations as potential therapeutic targets. We compared the data from the Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets in the USA with the data from Center for Cancer Genomics and Advanced Therapeutics in Japan.

Methods

We sequenced tumor DNA from 81 ES samples using the FoundationOne® CDx for multigene panel testing. Genetic alterations were interpreted via the Cancer Knowledge Database (CKDB) and potentially actionable alterations were classified into levels A–F.

Results

Analysis of 81 ES samples revealed 556 mutations in 197 genes and 126 copy-number alterations in 58 genes. Potentially actionable alterations were detected in 10 patients (12.3%) at CKDB levels A or C. STAG2 mutations accounted for 3.7%, TP53 mutations for 17.3%, and CDKN2A deletions for 13.6%. There was no significant difference in overall survival after genomic profiling test enrollment for STAG2 and TP53 mutations (P = .663 and P = .767), but those with CDKN2A and CDKN2B deletions had poor prognosis (P = .024 and P = .012).

Conclusion

Compared to previous reports, Japanese ES cases showed lower STAG2 and higher TP53 mutation frequencies. CDKN2A and CDKN2B deletions may serve as prognostic biomarkers indicating unfavorable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingBone NeoplasmsHumansMaleJapanFemaleAdultChildAdolescentYoung AdultMiddle AgedChild, PreschoolDatabases, GeneticMutationGenomicsAged

Stichwörter der Autor:innen

Ewing sarcomaThe Center for Cancer Genomics and Advanced Therapeutics (C-CAT) databasecBioPortal

Autor:innen und Institutionen

  • Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Division of Cellular Signaling, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Department of Orthopedic Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

ORCID-Profile: Satoshi Kamio, Koichi Ogura, Takafumi Koyama, Noboru Yamamoto, Hiroya Kondo, Toshiyuki Takemori, Eisuke Kobayashi, Shintaro Iwata

Zitieren

APA

Kamio, S., Ogura, K., Suehara, Y., Kitada, R., Ikegami, M., Sunami, K., Koyama, T., Yamamoto, N., Shimomura, S., Kondo, H., Takemori, T., Osaki, S., Kobayashi, E., Iwata, S., Kohsaka, S., & Kawai, A. (2026). Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf174

Vancouver

Kamio S, Ogura K, Suehara Y, Kitada R, Ikegami M, Sunami K, et al. Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf174

BibTeX
@article{Kamio2026,
  author = {Kamio, Satoshi and Ogura, Koichi and Suehara, Yoshiyuki and Kitada, Rina and Ikegami, Masachika and Sunami, Kuniko and Koyama, Takafumi and Yamamoto, Noboru and Shimomura, Seiji and Kondo, Hiroya and Takemori, Toshiyuki and Osaki, Shuhei and Kobayashi, Eisuke and Iwata, Shintaro and Kohsaka, Shinji and Kawai, Akira},
  title = {Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyaf174}
}
Kostenlos starten →